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              Abstract 
Background: Snakebite is generally considered medical emergencies in many parts of the world, particularly in 
the rural population, and has been linked with the environmental and occupational conditions. Agricultural workers 
and pediatric groups are most affected in Southeast Asia especially India. This study was conducted to analyze the 
clinical profile, complications, and outcome of snakebite that will help in the prevention and treatment intervention 
in the pediatric population. 
Methods: The present study was conducted at the pediatric tertiary center, Niloufer Hospital, Osmania Medical 
College, Hyderabad, India during the period of 1 year from January 2019 to December 2019. A total of 59 cases of 
snakebite were admitted to the pediatric department during the study period. After obtaining consent, data were 
analyzed for demographic data and other variables included are the site of the bite, time of the bite, time of arrival to 
hospital  and type of snake, features  of hematotoxicity  and neurotoxicity, ASV requirement, complications, and 
outcome.  
Results: Out of a total of 59 patients, 55.93% were male and most of the Snakebites were seen in the age group of 7-
12 years. Clinically 48(81.35%) patients presented with signs and symptoms of envenomation and most of them 
were bitten during the months of June to July. Greater number of bites were unknown Snakebites and lower 
limb(57.62%) was the commonest site of the bite. Most of the Snakebites i.e. 23(38.98%) happened during evening 
time and 15 (25.42%) cases during night time. Most of the patients were primarily treated by medical personnel. 
Majority of patients (32.03%)  developed clinical manifestations in 30 min to 1-hour duration followed by 13 cases 
(22.03%) within 30 min. Majority of patients (38.98%)  arrived at the hospital in 3-6 hours. During hospital 
treatment, 79.66% of victims received anti-snake venom (ASV). Mechanical ventilation required in 12 cases 
(20.33%) in which the majority of cases (8.47%) were unknown Snakebites. The most common complication was 
cellulitis (20.33%) followed by respiratory paralysis/coma (15.25%) and coagulopathy (6.77%). Abdominal pain 
was observed in 11 (18.64%) cases and Abdominal pain was co-existed with neuromuscular paralysis ( 90.90%). 
Acute kidney injury was seen in 1 case (1.69%).  
Conclusion: The most endangered group of children for Snakebites are boys aged more than 6 years. As most of the 
bites take place in lower limbs during evening hours, avoidance of outdoor activities, and protective clothing may 
significantly reduce the incidence of Snakebites. The presence of abdominal pain followed by neurotoxicity 
suggesting that pain abdomen is a potentially early feature of snakebite envenomation. Community education about 
prevention and first aid treatment, early transport, and admission in a hospital with good equipment will reduce the 
mortality from the snakebite. 
Keywords: Snakebite, Snakebite envenomation, Neuroparalysis in children, Pain abdomen, Anti-snake venom. 
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Introduction  
Snakebite envenomations kills large number of people 
in every year worldwide especially in rural population 
in developing contries[1,2]. Most of the Snakebites and 
deaths are registered in Asia and  Africa and it has 
estimated that 81000 Snakebites  with 11000 deaths 
occur in each year in India[3]  but according to India’s 
latest national health profile (published in 2018) there 
were 1,42,366 Snakebites with 948 deaths occurred. 
This may be due to under reporting of Snakebites as 
many snakebite victims could not reach hospital. Most 
Snakebites occur in agricultural workers during rainy 
season in developing nations like india[4]. Snakes are 
most likely to bite human being when the snake is 
trodden on, by someone who is bare footed, when 
snake comes in to the home at night (usually krait) in 
search of its food, and when sleeping on floor. WHO 
has promulgated that Snakebite is a neglected tropical 
diseases as Snakebite envenomation is become public 
health hazard in tropical and subtropical region in June 
2017[5]. The  highest number of Snakebites were seen 
in india and it account for high mortality globally 
[3].Children and young adults are the factors associated 
with severe envenomation as large amount of venom 
relative to body surface area[7].There is about 52 
snakes are known to be poisonous in india includes 
Elapidae family (common cobra, king cobra and krait), 
viperidae family (russells viper) and hydrophidae 
family(sea snakes) in which viperidae and elapidae 
families are medically significant venomous snakes. 
The peak age for Snakebite is school age children, 
adolescent and young adults and peak fatality rate is in 
young children and the elderly (WHO UNICEF, 2008). 
The risk of envenomation and clinical manifestations 
depends on species and type of bite such as dry bite or 
wet bite in children.  Some time it may be strongly 
suspected from parents description or circumstances of 
the bite or known effects of venom of snake species. 
Snakebite is one of the common  morbidity and 
mortality in rural set up. As a result, Snakebite is 
considred as important medical emergency and  
admission in health center. So, this prospective 
descriptive study was carried  out to ascertain clinical 
profile, complications and outcome of Snakebite in 
pediatric population. 
 
Materials and Methods 
 
The present study was conducted at pediatric tertiary 
center, Niloufer hospital, Osmania Medial College, 
Hyderabad, India during period of 1 year from January 
2019 to December 2019.  
 
Inclusion criteria 
Patients of age less than 12 years in  Telangana region 
admitted with suspected or confirmed Snakebite.  
Exclusion criteria 
1. Patients brought dead with history of Snakebite. 
2. Cases of unknown bites in the absence of fang 
marks or any other symptoms not suggestive of 
venomous Snakebites were also excluded. 
A total of 59 cases of Snakebite were admitted in 
pediatric department during the study period. After 
obtaining consent data was collected on predesigned, 
pretested and structured questionnaire by interviewing 
the parents of the study subjects.  
A detailed information regarding demographic and 
epidemiological parameters such as age, sex, residence, 
site of bite and place of bite , type of snake if identified 
etc. was obtained. Time interval to reach the health 
facility after Snakebite and first aid received if any was 
asked. Time interval between Snakebite and clinical 
manifestations suggestive of hematotoxicity, neuro 
toxicity and local symptoms including fang marks, 
condition of the wound and initiation of treatment were 
recorded. A detailed systemic and local examination 
was carried out in all patients. Routine and specific 
investigations were done,  including complete 
hemogram, peripheral smear, renal function test, liver 
function test, BT, CT, whole blood clotting time. 
According to WHO protocol patients were treated with 
polyvalent anti-snake venom[11,8].The specific 
antidote for snake venom is anti-venom which is a 
immunoglobulin purified from plasma of horse. 
Antivenom can be monovalent (specific for one species 
of snake) or polyvalent. In India each milliliter of 
polyvalent anti-venom is supposed to neutralize 0.6 mg 
of Indian cobra venom , 0.6 mg of russel viper venom, 
0.45 mg of common krait venom, 0.45 mg of saw scald 
viper venom[12,9].According to the severity of 
symptoms freeze-dried antivenom is reconstituted with 
10 ml of sterile water then 50-150 ml of ASV was 
diluted with 200 ml of normal saline and infused at a 
constant rate over a period of 1 hr. During hospital stay 
complications and sequelae were noted. Resuscitation, 
requirement of ventilation and duration of ventilation 
was obtained.  
 
Results  
 
A toal of 59 cases of Snakebites, under 12 years of age 
were analyzed. Among them 33 (55.93%) were males 
and 26 (44.06%) were females. The highest incidence 
of Snakebite was observed in the age group of 7 12 
years (64.40%), followed by 33.89% in the age group 
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of 2 to 6 years and least i.e. 1.69% in the age group of 
less than 1 year.(Table I) .A majority of the cases were 
from the rural area (83.05%) and remaining (16.94%) 
were from urban patients. Among urban patients 8.47% 
cases were bitten in outdoor and 6.77% cases from 
indoor bites. Lower limbs were the most common site 
of bites where marks were seen in 34 patients 
(57.62%). This is followed by upper limbs (20.33%) 
which had  bite marks and head & face (03.38%). 
Unknown site of Snakebite were seen in 11 cases 
(18.64%).(Table I) Most of the Snakebites i.e. 
23(38.98%) occurred during evening time and 15 
(25.42%) cases during night time. Nine cases (15. 
25%) were reported in early morning followed by 
8.47% cases in morning and 6.77% cases in day 
time.(Table II) Majority (44.06%) of the bites were 
unknown Snakebites. In known Snakebites 18.64% 
were admitted with viper bites, 8.47% with cobra bites 
and 11.86% with krait bite. Suspected Snakebites were 
recorded in 16.94% of cases. (Table II)Regarding the 
seasonal variation maximum Snakebites were observed 
during the period of Jun (22.03%) –July (20.33%), 
which coincides with the rainy season in India.(table 
III).Majority of patients (32.03%)  developed clinical 
manifestations in 30 min to 1 hour duration followed 
by 13 cases (22.03%) within 30 min.  In 6 cases 
(10.16%) clinical manifestations developed after 6 
hours. Majority of patients (38.98%)   reached hospital 
in 3-6 hours followed by 16 cases (27.11%) in 1-3 hrs 
and 15 cases (25.42%)  reached  after 6 hours. Among 
59 Snakebite cases, maximum (40.67%) were having 
swelling at the site of bite followed by pain (22.04%), 
ptosis/ ophthalmoplegia (22.03%), pain abdomen 
(18.64%), altered sensorium/ drowsiness (13.55%) and 
bleeding from bite site (11.86%). Other manifestations 
include itching (1.69%), blisters (5.08%), fever 
(3.38%), vomiting (8.47%), limb weakness (5.08%) 
and seizures (1.69%). Fang  marks were seen in 34 
cases (57.62%). There were no signs of envenomation 
in 11 cases (18.64%) and 49 cases (83.05%) had 
history of Snakebite. Among the neuroparalytic bites, 
11 patients  presented with abdominal pain which was 
the main presenting complaint. (Table IV). In most 
cases (57.62%) the victims received no first aid 
immediately after the bite. During hospital treatment, 
79.66% of victims received anti-snake venom(ASV) 
treatment. Among 59 cases 4.77% cases needed 
resuscitation. Mechanical ventilation was required in 
12 cases (20.33%) in which majority cases (8.47%) 
were unknown Snakebites followed by suspected  
4cases (6.77%), cobra  2(3.38%) and krait 1 case(1.69). 
(table VI). Out of 12 ventilated cases, 6 cases needed 
ventilation for 24 hours and one case required more 
than 72 hours. In our study 5-10 ASV vials were 
required in 12 (20.33%) cases followed by 16-20 vials 
in 8 (13.55%)  cases. In 4 (6.77%) cases patients 
required more than 60 vials and maximum 80 vials 
were given in 1 case. No ASV was given in 12 cases 
(20.33%).  In most cases (30.50%) ASV was given in 1 
cycle and 5 cases (8.47%)  required more than 6 cycles. 
(Table V).Most common complication was cellulitis 
(20.33%) followed by respiratory paralysis/coma 
(15.25%) and coagulopathy (6.77%). Acute kidney 
injury was seen in 1 case (1.69%). Reaction to ASV 
was seen in 4 cases(6.77%) . (table IV)After admission 
to this hospital 52 (88.13%) cases were completely 
cured, 4 (6.77%) cases died and 3 (05.08%) cases 
absconded.(table VII)  
 
Discussion 
 
The most affected  age group for Snakebites in our 
study was children over 6 years of age because they are 
engaged in outdoor games and activities like grass 
cutting, cattle grazing in rural area. In this study, 
64.40% of the total cases belonged to age group 7-12 
years. Similar types of age distribution were reported 
by Kumaravel KS et al[10], Chandrashekar C et al[11], 
Krishana VM et al[12]. Incidence was more in boys 
(55.93%) as compared to girls (44.06%), this is similar 
to other studies as  boys are  more active in outdoor 
games[13,14].In the present study, most of the 
snakebite cases were from rural areas (83.05%) and 
were outdoor incidents (57.14%).Snakebites are more 
common on the lower extremities because children 
have bitten by snake  whilewalking or playing in the 
evening and night[15].  We found that 34 (57.62%)   
patients had bite marks on thelower limbs similar to 
various studies which have shown that in 70-86% 
patients bite marks arepresent on the lower 
limbs[16,17]. 20.33% bite marks were seen on the 
upper limbs as children are curious about hiding places 
of snakes such as crevices.The majority of Snakebite 
envenomations  which occurred during evening(17:00-
19:59) and night i.e., 20:00 to 4:59 hour (Table 2). 
Those who have bites in evening and night were 
developed neurotoxicity in large number. Previous 
studies support this association, as Common Kraits are 
most injurious during the night hours [18,19].Majority 
of the Snakebites were happened in the month of June- 
July, similar finding was obtained by Bawaskar and 
Bawaskar[19].Majority of the bites were unknown 
Snakebite (44.06%) in the present study as children are 
not able to identify type of snake species. Among 
known bites viper bite was more common (18.64%) 
than krait (11.86%) and cobra (8.47%) bites. In 
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contrast, study conducted by Shyna et al[20] showed 
that majority of the bites were viper (46%) followed by 
unknown bites (36%). Another study conducted by 
Amitabha et al[21] showed that greater number of the 
bites were by Elapids (46%) followed by viper (38 
%).It was observed that only a few of the patients 
attended hospital within the 1st hr of bite and the 
greater attended between 1st and 6 hrs. 16 patients 
arrived at this hospital after 12 hrs of bite. This delay 
was associated with poor prognosis. The delay from 
bite to treatment dissimilar in studies from different 
health care centers in India[22,23].  We observed that 
38.98% cases arrived to the hospital within 3 to 6 hour 
of bite, 27.11% cases within 1 to 3 hours and 
remaining after 6 hours of bite. In a similar study 
conducted by Shyna et al[21], 86% of the subjects 
reached hospital within 6 hours. Most of the patients 
had developed clinical manifestations within 1hour of 
Snakebite. Among neurotoxic bites pain abdomen, pain 
at local site (22.03%) altered consciousness (13.55%) 
and ptosis/ophthalmoplegia (22.03%) were noted. 
Similar features were reported by Gautam P et al[24], 
Adhisivam B et al[25].In our study the presenting 
symptoms were swelling (40.67%) and bleeding 
(11.86%) from the site of bite. On local examination 
we observed bite marks in 57.62% cases and blister 
formation in 5.08% cases.  Abdominal pain was 
observed in 11 (18.64%)  cases and Abdominal pain 
co-existed with neuromuscular paralysis ( 90.90%). 
Similar to kularatne at al[26].Most of the snakebite 
victims received ASV vials upto 20, in few cases more 
than 60 vials were given in this study. Some studies 
described lower doses of antivenom (average vials = 
16, range 2–140 vials [27,28].Some other studies 
showed that no differences between higher and lower 
dosage of ASV infusion in terms of 
mortality[29].Mechanical ventilation was required in 
12 cases (20.33%) in which majority cases (8.47%) 
were unknown Snakebites followed by suspected  
4cases(6.77%), cobra  2(3.38%) and krait 1 case(1.69). 
These unknown and suspected Snakebites were could 
be neurotoxic bites as children are not able to identify 
type of snake .In most cases (57.62%) the victims 
received no first aid (tourniquet, herbal, blood sucking, 
TT injections and ASV in PHCS) immediately after the 
bite. During Snakebite management, 79.66% of victims 
received anti-snake venom (ASV).  The most effective 
treatment for Snakebite envenomation is IV 
infusion[30]. Now  anti snake venom is available in all 
public hospitals with free of cost, particularly in the 
remote rural areas also as awareness of ASV is 
increased. Cellulitis is the most common finding as 
observed in Meshram RM et al[31]. Acute renal failure 
developed in 1 (0.68%) patient who had presented 8 
hours after the bite reported by kshirsagar VY,et 
al[32].The overall mortality rate in the present study 
was 6.77%. The mortality rate was 10.3 % reported by 
Jayakrishnan et al[33].Immediate death after Snakebite 
is rare but it can happen after many hours in case of 
elapid bites  and it may takes days in viper bites. 
Mortality rate after Snakebite depends upon various 
factors like amount of venom injected, site of bite 
(serious if bitten on the trunk or head, neck and face), 
species and size of the snakes, and time to arrival to the 
hospital. It also depends on age the victim( as 
envenomation in a child is serious and fatal) and 
availability of ICU care.  
 
Conclusion  
 
The most endangered group of  children for Snakebites 
are boys aged more than 6 years. As most of the bites 
take place in lower limbs during evening hours , 
avoidance of outdoor activities and protective clothing 
may significantly reduce the incidence of Snakebites. 
Presence of abdominal pain followed by neurotoxicity 
suggesting that pain abdomen is a potentially early 
feature of Snakebite envenomation. Community 
education, early arrival and admission in a hospital 
with well equipment  will reduce the mortality from 
Snakebite. 
 
Table-1:Demographic data 
Age and  Sex wise distribution 
Age group Male (%) Female (%) Total (%) 
0-1yr 
2-6yr 
7-12yr 
total 
1(1.69) 
12(20.33) 
20(33.89) 
33(55.93) 
0 
8(13.55) 
18(30.50) 
26(44.06) 
1(1.69) 
20(33.89) 
38(64.40) 
59 
Site distribution of Snakebite 
Site  No. of  patients (%) 
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Lower extremity  
Upper extremity  
Head, Neck and Face  
Trunk   
Unknown    
Total 
34(57.62) 
12(20.33) 
2(3.38) 
0 
11(18.64) 
59 
 
Table-2:  Timing of Snakebite and type of snake 
Timing of Snakebite No. of  patients (%) 
Early morning(03:00-04:59) 
Morning(05:00-09:59) 
Day (10:00-16:59) 
Evening (17:00_19:59) 
Night (20:00-02:59) 
Unknown  
total 
9(15.25) 
5(8.47) 
4(6.77) 
23(38.98) 
15(25.42) 
3(5.08) 
59 
Type of snake No. of  patients (%) 
Cobra  
 Viper  
Krait  
Unknown snake  
Suspected  snake 
05 (8.47%) 
11(18.64%) 
07(11.86%) 
26(44.06%) 
10(16.94%) 
 
Table-3:Month wise  distribution  of Snakebite 
Month  No. of  patients (%) 
January  2 (3.38) 
February  5 (8.47) 
March  4 (6.77) 
April  2 (3.38) 
May  4 (6.77) 
June  13 (22.03) 
July  12 (20.33) 
August  8 (13.55) 
September  2 (3.38) 
October  3 (5.08) 
Novemer  4 (6.77) 
December  0 
Total  59 
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Table-4:Clinical manifestations and Complications 
Clinical manifestations No. of  patients (%) 
History of Snakebite 
No envenomation 
Local symptoms/signs 
Fang marks  
Pain/tenderness 
Itching 
Swelling 
Blister 
Bleeding from bite site 
Systemic symptom/signs 
Fever 
Vomiting 
Pain abdomen 
Ptosis/ophthalmoplegia 
Limb paresis 
Altered sensorium/drowsiness 
Seizures 
Complications 
Cellulitis 
Respiratory paralysis/coma 
Acute kidney injury 
Coagulopathy 
Reaction to ASV 
death 
49(83.05) 
11(18.64) 
 
34(57.62) 
13(22.03) 
1(1.69) 
24(40.67) 
3(5.08) 
7(11.86) 
 
2(3.38) 
5(8.47) 
11(18.64) 
13(22.03) 
3(5.08) 
8(13.55) 
1(1.69) 
 
12(20.33) 
9(15.25) 
1(1.69) 
4(6.77) 
4(6.77) 
4(6.77) 
Table-5:Treatment -Average ASV vials & cycles 
No. of ASV vials No. of patients (%) 
No vials 
Less than 5 
5-10 
11-15 
16-20 
21-25 
26-30 
31-40 
41-50 
51-60 
More than 60 
12(20.33) 
6(10.16) 
12(20.33) 
6(10.16) 
8(13.55) 
2(3.38) 
6(10.16) 
1(1.69) 
1(1.69) 
1(1.69) 
4(6.77) 
No. of cycles No. of patients (%) 
1cycle 
2 
3 
4 
5 
>6 
18(30.50) 
12(20.33) 
10(16.94) 
1(1.69) 
1(1.69) 
5(8.47) 
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Table- 6: Requirement of  ASV, Resuscitation and Mechanical ventilation 
Type of snake                        No. of  patients (%) required 
ASV Resuscitation Mechanical ventilation 
Cobra 
Viper 
Krait 
Unknown Snakebite 
Suspected Snakebite 
total 
 5(8.47) 
11(18.64) 
5(8.47) 
18(30.50) 
8(13.55) 
47(79.66) 
1(1.69) 
0 
0 
3(5.08) 
0 
4(6.77) 
2(3.38) 
0 
1(1.69) 
5(8.47) 
4(6.77) 
12(20.33) 
 
Table-7: Outcome of Snakebite 
Type of Snakebite Death (%) Recovered (%) Absconded/LAMA 
Cobra 
Viper 
Krait 
Unknown Snakebite 
Suspected Snakebite 
total 
1(1.69) 
0 
0 
2(3.38) 
1(1.69) 
4(6.77%) 
4(6.77) 
11(18.64) 
7(11.86) 
21(35.59) 
8(13.55) 
52(88.13%) 
0 
0 
0 
2(3.38) 
1(1.69) 
3(5.08%) 
 
References 
 
1. Warrell DA. Snakebite. Lancet 2010;375:77-88. 
2. World health organization:world health ststistics 
2007.geneva:WHO;2007.http://www.who.int/ 
whosis/ whostat  2007en/. Accessed 29 september 
2008. 
3. Kasturiratne A, Wickremasinghe R, de Silva N, 
Gunawardena K, Pathmeswaran A, Premaratne R, 
Salvioloi L, Lalloo DG, de Silva HJ: The global 
burden of snakebite: a literature analysis and 
modeling based on regional estimates of 
envenoming. PLoS Med 2008, 5:e218. 
4. Boyd JJ, Agazzi G, Svajda D, et al.Venomous 
snakebite inmountainous terrain: Prevention and 
management.Wilderness Environ Med 2007; 18: 
190-202. 
5.  Savioli L. Neglected Tropical Diseases. Available 
from: http://www.who.int/ neglected_ disease/ 
Savioli_ presentation.pdf?ua=1  
6. Kasturirantne A, Wickremasinghe AR, Silva N, 
Gunawardena NK, Pathmeswaran A. The global 
burden of Snakebite: a literature analysis and 
modeling based on regional estimates of 
envenoming and deaths. PloS Med. 2008; 5(11) 
:218. 
7.  Habib AG. Public health aspects of snakebite care 
in West Africa: perspectives from Nigeria. J 
Venom Anim Toxins Incl Trop Dis. 2013;19(1) 
:27.  
8. Warrell DA. Epidemiology of Snakebite in South 
East Asia Region. In: Warrel DA(ed) Guidelines 
for management of Snakebite. New Delhi: WHO 
regional office for South Asia. 2010;1:135.  
9. Bawaskar HS, Bawaskar PH. Profile of snake 
envenoming in western Maharashtra India. Trans 
Roy Soc Trop Med Hyg 2002;96(1):79-84.  
10. Kumaravel KS, Ganesh J. A study on the clinical 
profile of children with snake envenomation in a 
tertiary referral centre at Dharmapuri, Tamilnadu, 
India. Int J Res Med Sci. 2016;4(6):2142-5.  
11. Chandrashekar C, Shariff MA, Gopal K, 
Ravichander B. Clinical profile of snakebite in 
children. J Evidence Based Medi Healthcare. 
2015;(29):4176-84.  
12. Krishana VM, Sheikh NA, Soren C. Clinical 
profile and outcome of Snakebite envenomation in 
Meshram RM et al. Int J Contemp Pediatr. 
2017;4(3):910-914  .  
13. Sani UM, Jiya NM, Ibitoye PK, Ahmad MM. 
Presentation and outcome of Snakebite among 
children in Sokoto. North-western Nigeria. Sahel 
Med J. 2013;16(4):148-53.  
14. Reddy MP, Sudharshan RC. Clinical, 
epidemiological and hematological profile of 
Snakebite in children in rural teaching hospital. Int 
J Health Sci Res. 2015;5(7):58-63.  
International Journal of Health and Clinical Research, 2020;3(4):5-12                     e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Pandala et al               International Journal of Health and Clinical Research, 2020; 3(4):5-12 
www.ijhcr.com                              
        12 
 
15. Digra S, Singh V. A clinical profile of neurotoxic 
snakebite in pediatric population of Jammu region. 
JK Sci. 2016;18(2):67-70.  
16. Punde DP. Management of snake-bite in rural 
Maharashtra: A 10-year experience. Natl Med J 
India 2005;18(2):71-5. 
17. Shrestha BM. Outcomes of snakebite envenom-
mation in children. J Nepal Paediatr Soc 2011; 31 
(3):192-7.  
18. Ariaratnam, CA, Sheriff, MHR, Theakston, RDG 
and Warrell, DA. Distinctive epidemiologic and 
clinical features of Common Krait (Bungarus 
caeruleus) bites in Sri Lanka. Am J Trop Med 
Hyg, 2008; 79: 458–462. 
19. Bawaskar, HS and Bawaskar, PH. Envenoming by 
the Common Krait (Bungarus caeruleus) and 
Asian Cobra (Naja naja): clinical manifestations 
and their management in a rural setting. 
Wilderness Environ Med, 2004; 15: 257–266. 
20. Shyna K, Sudhakaran K, Mohammed M. A 
clinical profile of poisonous Snakebite in children 
of North Kerala, India. International Journal of 
Contemporary Pediatrics. 2018;5(2):310-3. 
21. Amitabha Pal. Clinical Profile and outcome of  
Snakebite in patients attending a tertiary care 
hospital in Bankura, West Bengal. IOSR Journal 
of Dental and Medical Sciences. 2018;17(10):34-
39. 
22. Srimannarayana J, Dutta TK, Sahai A, Badrinath 
S. Rational use of anti-snake venom (ASV): Trial 
of various regimens in hemotoxic snake 
envenomation. J Assoc Physicians India 2004; 52: 
788-93. 
23. Narvencar K. Correlation between timing of ASV 
administration and complications in Snakebites. J 
Assoc Physicians India 2006;54:717-9. 
24. Gautam P, Sharma N, Sharma M, et al. Clinical 
and demographic profile of snake envenomation in 
Himachal Pradesh, India. Indian Pediatr. 2014;51 
(11): 934-5. 
25. Adhisivam B,Mahadevan S. Snakebite envenom-
mation in India: a rural medical emergency. Indian 
Pediatr. 2006;43(6):553-4. 
26. Kularatne SAM, Silva A, Weerakoon K, 
Maduwage K, Walathara C, et al. Revisiting 
Russell’s Viper (Daboia russelii) Bite in Sri 
Lanka: Is Abdominal Pain an Early Feature of 
Systemic Envenoming? PLoS ONE 2014;9(2): 
e90198. 
27. Sharma, SK, Khanal, B, Pokhrel, P, Khan, A and 
Koirala, S. Snakebite-reappraisal of the situation in 
eastern Nepal. Toxicon, 2003;41: 285–289. 
28. Magar, CL, Devkota, K, Gupta, R, Shrestha, RK, 
Sharma, SK and Pandey, DP. A hospital based 
epidemiological study of snakebite in Western 
Development Region, Nepal.Toxicon, 2013;69: 98 
–102. 
29. Paul, V, Pratibha, S, Prahlad, KA, Earali, J, 
Francis, S and Lewis, F. High-dose anti-snake 
venom versus low-dose anti-snake venom in the 
treatment of poisonous snakebites – a critical 
study. J Assoc Physicians India, 2004;52:14–17. 
30. Faiz MA (2006) Snakebite and its treatment. 
Dhaka: M J Akter. 69 p. 
31. Meshram RM, Bokade CM, Merchant S, 
Bhongade S. Clinical profile and outcome of 
Snakebite in children. Int J Contemp Pediatr 2017 
;4:910-4. 
32. Kshirsagar VY, et al. Clinical Profile of Snakebite 
in Children in Rural India. Iranian Journal of 
Pediatrics, 2013; 23 (6):632-636. 
33. MP Jayakrishnan, MG Geetha, P Krishnakumar, 
TV rajesh, Biju Geoege. Archives of disease in 
childhood, 2017;102 (5):445-449. 
 
 
Source of Support:Nil 
Conflict of Interest: Nil 
 
